Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01091337 |
Recruitment Status
:
Completed
First Posted
: March 24, 2010
Last Update Posted
: March 24, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Asthma | Drug: Procaterol Drug: Salbutamol | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 96 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Comparative Study on the Efficacy and Safety of Procaterol vs Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room |
Study Start Date : | May 2006 |
Actual Primary Completion Date : | September 2009 |
Actual Study Completion Date : | September 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: Procaterol
Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment |
Drug: Procaterol
Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment Other Name: Meptin Air
|
Active Comparator: Salbutamol
Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
|
Drug: Salbutamol
Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
Other Name: Ventolin Inhaler
|
- To evaluate the bronchodilator efficacy of inhaled procaterol (Meptin Air) vs. inhaled salbutamol used as MDI reliever of acute exacerbation of asthma in the ER. [ Time Frame: < 12 hours ]
- To evaluate the safety of procaterol MDI (Meptin Air) versus salbutamol MDI in the management of acute exacerbation of asthma in terms of adverse side effects such as palpitations, tachycardia, tremor, and hypokalemia. [ Time Frame: < 12 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adult patients aged 20 years old and above who are brought to the Emergency Room (ER) with acute bronchospasm
- Diagnosed cases of bronchial asthma based on history, physical examination and pulmonary function test
- Patients maintained on inhaled steroids who have no active medical problems (such as pulmonary TB, cardiac and renal diseases) aside from asthma
- Presence of known risk factors for asthma mortality does not disqualify patients from the study unless they are in impending respiratory failure
- All patients must sign the informed consent form
Exclusion Criteria:
- Patients who are in respiratory distress consistent with severe exacerbation requiring intensive care hospital admission
- Who had intake of oral bronchodilator 6 hrs prior to consult
- Who had intake of oral steroids within the last 24 hrs
- Those with positive history of allergy and hypersensitivity to procaterol and salbutamol
- Patients who are diagnosed or clinically suspected to have COPD (ever-smokers with >10 pack-years smoking history or those exposed to workplaces where there is a heavy smoke load)
- Presence of concurrent disease/diseases that may aggravate asthma thereby delaying bronchodilator response (e.g., pneumonia, pulmonary congestion and others)
- Patients with other medical conditions which are serious enough to warrant immediate concurrent therapy during the 1 hour study and/or whose condition can be adversely affected by the treatment given (like uncontrolled diabetes, renal failure and hepatic insufficiency)
- The NIH Working Group on Asthma and Pregnancy has recommended that pregnant asthmatics are treated as aggressively as non-pregnant patients particularly during acute asthmatic attack. , Bronchodilators (except for epinephrine which is not in this study) have been found safe in pregnancy with a risk class of B and C. For these reasons, pregnancy by itself is not an exclusion criterion in this study and a pregnancy test will not be required for those who are in the childbearing age group. Requiring the test will unnecessarily delay the treatment for acute asthma. However, those who are suspected to be suffering from pregnancy-related complications like vaginal bleeding, premature labor, pre-eclampsia and others, are excluded.
-
Severe Acute Asthma Attack, a reason for patient exclusion, shall be defined in this study as the presence of any one of the following criteria:
- Severe asthma with a lack of response to initial therapy in the emergency department or worsening asthma despite adequate therapy.
- Presence of confusion, drowsiness, other signs of impending respiratory arrest, or loss of consciousness
- Wood-Downe's clinical asthma scoring score of >5 (see table 2 below)
- Any patient who is currently participating in other drug trials and/or having participated in other drug trials for less than 1 month of termination of the trial are excluded
- Patients who have previously participated in this study are excluded

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01091337
Philippines | |
Philippine General Hospital | |
Manila, Philippines |
Principal Investigator: | Camilo Roa, MD | Philippine General Hospital |
Responsible Party: | Dr. Camilo Roa, MD / Study Principal Investigator, Philippine General Hospital |
ClinicalTrials.gov Identifier: | NCT01091337 History of Changes |
Other Study ID Numbers: |
KOIAA-MPT-2005-01 |
First Posted: | March 24, 2010 Key Record Dates |
Last Update Posted: | March 24, 2010 |
Last Verified: | March 2010 |
Additional relevant MeSH terms:
Asthma Emergencies Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Disease Attributes Pathologic Processes Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Cortisol succinate |
Hydrocortisone Albuterol Procaterol Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Tocolytic Agents Reproductive Control Agents Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists |